Orchestra BioMed Presents BACKBEAT Trial Update, Targets Primary Data in Q2 2027
Bitget2026/11/12 15:48- Orchestra BioMed surpassed its BACKBEAT pivotal trial enrollment target, randomizing 349 patients.
- Primary endpoint data for AVIM Therapy are targeted for presentation at HRS in the second quarter of 2027.
- Potential FDA approval and Medtronic commercial launch are targeted for the first half of 2028.
- Current cash provides runway through 2028; strategic partners have invested or paid more than $185 million.
- The Medtronic collaboration provides an uncapped, double-digit royalty-based revenue share on every AVIM Therapy-enabled device sold.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Don't be scared by the Nvidia turmoil and election noise! Morgan Stanley: AI turbulence does not change the main driver of the bull market, long-term outlook remains "extremely bullish"
The Chief Investment Officer of Morgan Stanley Wealth Management stated that management turmoil at Nvidia and the Democratic Party's victory in the midterm elections have further heightened market concerns about the AI sector. However, these factors will not shake the core driving force of this bull market—capital expenditure on AI infrastructure.
After Jensen's resignation, the "Big Short" doubles down on shorting tech stocks! Warns the AI boom may turn into a "bull trap"
Michael Burry increased his short positions following Huang Renxun's resignation. He compared Nasdaq’s October peak to the top of the 2000 internet bubble. On November 12th, he doubled his put option positions on the Nasdaq 100, with expiry set for early 2027, and rebuilt put options on the VanEck Semiconductor Index. He directly warned investors to "exit the market" and predicted a significant correction in chip stocks before mid-2027.
Tesla (TSLA.US) Cybercab limited pre-orders open: priced at $29,990, with an additional monthly operating fee of $299
According to reports, Tesla has invited select customers to reserve the Cybercab, taking a step toward launching this self-driving model to general consumers.
Fed Vice Chair Sets the Tone: Inflation Is the "Most Important Signal," Interest Rate Decisions Depend on It
Federal Reserve Vice Chair Philip Jefferson stated that when policymakers consider whether to raise interest rates further, inflation has become the most important metric.
Crypto prices
More
